MGMT and glioblastoma: A phase III clinical trial comparing nivolumab plus radiotherapy with standard chemoradiotherapy further confirmed that patients with de novo O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma did not benefit from nivolumab therapy (CheckMate-498) [118].